Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bridgebio Pharma Inc
(NQ:
BBIO
)
30.09
-0.95 (-3.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bridgebio Pharma Inc
< Previous
1
2
3
Next >
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
October 10, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
October 09, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
October 03, 2023
From
National Resilience, Inc.
Via
Business Wire
BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 8/18
August 18, 2023
Via
Investor Brand Network
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
October 03, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
September 25, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 07, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
September 06, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
August 27, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
August 24, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
August 03, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study
July 31, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 18, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio (NASDAQ: BBIO) Announces Exceptionally Positive Outcomes in Phase 3 Study of Acoramidis
July 17, 2023
BridgeBio Pharma (NASDAQ: BBIO), a leading biopharmaceutical company, announced significant outcomes from the ATTRibute-CM, their Phase 3 study of acoramidis,
Via
Spotlight Growth
BridgeBio Pharma Inc. (NASDAQ: BBIO) Records 52-Week High Monday Morning
July 17, 2023
Via
Investor Brand Network
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
July 17, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023
July 14, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma
July 12, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
June 20, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 13, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference
June 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 22, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 15, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 11, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
May 04, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
April 27, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 11, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 07, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.